Suppr超能文献

从人胃癌肿瘤相关淋巴细胞体外生成免疫效应细胞。

In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer.

作者信息

Kim H J, Heo D S, Suh C I, Kim H T, Bang Y J, Kim N K

机构信息

Department of Internal Medicine, Dong-A University Hospital, Busan, Korea.

出版信息

Anticancer Res. 1995 Jul-Aug;15(4):1247-55.

PMID:7654004
Abstract

Despite recent advances in cellular immunotherapy of cancer, the effectiveness of this type of treatment is limited only to some types of cancer. This study was performed to generate tumor-specific cytotoxic T lymphocytes (CTL) for the treatment of gastric cancer and to find the optimal culture conditions for this CTL, because most immune effector cells used in the previous trials were non-specific killers. Lymphocytes were isolated from tumors, tumor-draining lymph nodes, malignant ascites and peripheral blood of 29 patients with gastric cancer. Lymphocytes from each source were then cultured for three weeks under one or more of the following conditions: 1) 50 U/ml of rIL-2; 2) 50 U/ml of rIL-2 + irradiated (6,000 rad) fresh autologous tumor cells (in vitro sensitization - IVS); 3) 1,000 U/ml of rIL-2; 4) 1,000 U/ml of rIL-2 + IVS. The study found that 1,000 U/ml of rIL-2 generated higher cytotoxicity against allogeneic tumor targets than 50 U/ml of rIL-2 (p < 0.05). However, neither the concentration of rIL-2, lymphocyte source, nor IVS produced any significant differences in cytotoxicity against fresh autologous tumor cell targets. The data suggested that immune effector cells for gastric cancer could be generated efficiently, but it was difficult to produce CTL specific for autologous tumor cells of gastric cancer using a low concentration of rIL-2 and/or in vitro sensitization with autologous irradiated tumor cells.

摘要

尽管癌症细胞免疫疗法最近取得了进展,但这种治疗方式的有效性仅局限于某些类型的癌症。进行这项研究是为了产生用于治疗胃癌的肿瘤特异性细胞毒性T淋巴细胞(CTL),并找到这种CTL的最佳培养条件,因为之前试验中使用的大多数免疫效应细胞都是非特异性杀手。从29例胃癌患者的肿瘤、引流肿瘤的淋巴结、恶性腹水和外周血中分离淋巴细胞。然后将来自每个来源的淋巴细胞在以下一种或多种条件下培养三周:1)50 U/ml的rIL-2;2)50 U/ml的rIL-2 + 经照射(6000拉德)的新鲜自体肿瘤细胞(体外致敏 - IVS);3)1000 U/ml的rIL-2;4)1000 U/ml的rIL-2 + IVS。研究发现,与50 U/ml的rIL-2相比,1000 U/ml的rIL-2对同种异体肿瘤靶标的细胞毒性更高(p < 0.05)。然而,rIL-2的浓度、淋巴细胞来源以及IVS对新鲜自体肿瘤细胞靶标的细胞毒性均未产生任何显著差异。数据表明,可以有效地产生用于胃癌的免疫效应细胞,但使用低浓度的rIL-2和/或用自体照射肿瘤细胞进行体外致敏很难产生针对胃癌自体肿瘤细胞的CTL。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验